Assay of Bio Analytical Method for the Estimation of Avelumab and Axitinib Using UPLC and Its Application to Pharmacokinetic Studies

Abstract

Aims: Bioanalytical methods for the estimation of Avelumab and Axitinib using UPLC have been validated and may be used in Pharmacokinetic investigations.
 Place and Duration of Study: Department of Engineering Chemistry, AUCE (A), Visakhapatnam, Andhra Pradesh, between September 2021 to February 2022.
 Methodology: Using a C18 column (50x2.1 mm, 1.7 ) and an organic mobile phase containing 0.1 percent formic acid and Acetonitrile in a 70:30 ratio, this article provides an overview of recent advances in bioanalytical UPLC procedures.
 Results: Avelumab and axitnib had linear calibration curves in the 5-100 ng/ml and 5-100 ng/ml ranges, respectively. Avelumab's precision and accuracy trial results were from 100.18 to 103.94, whereas Axitinib's were 99.39 to 100.81, according to the findings. The LQC and HQC of Avelumab and axitinib were 99.9 and 99.1 percent, respectively, in the matrix effect. There was a 0.67 and a 0.59 percent CV for the two medicines at the LQC and HQC levels respectively. In pharmacokinetic investigations, a simple and effective approach was created and used to observe the analyte of interest in bodily fluids.
 Conclusion: It shows that the system's appropriateness, precision, linearity, and accuracy are all in accordance with USFDA criteria and may be used successfully for pharmacokinetic research in rabbits.